dc.contributor.author | Buckingham, SD | en_US |
dc.contributor.author | Mann, H-J | en_US |
dc.contributor.author | Hearnden, OK | en_US |
dc.contributor.author | Sattelle, DB | en_US |
dc.date.accessioned | 2020-08-24T09:07:25Z | |
dc.date.issued | 2020-09 | en_US |
dc.identifier.issn | 0265-9247 | en_US |
dc.identifier.other | ARTN 2000011 | en_US |
dc.identifier.other | ARTN 2000011 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/66545 | |
dc.relation.ispartof | BIOESSAYS | en_US |
dc.rights | This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.subject | chemogenetic tool | en_US |
dc.subject | epilepsy | en_US |
dc.subject | L-glutamate-gated chloride channel | en_US |
dc.subject | ivermectin | en_US |
dc.subject | novel therapy | en_US |
dc.title | Turning a Drug Target into a Drug Candidate: A New Paradigm for Neurological Drug Discovery? | en_US |
dc.type | Article | |
dc.rights.holder | © 2020 The Authors. BioEssays published by Wiley Periodicals LLC | |
dc.identifier.doi | 10.1002/bies.202000011 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000557404700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 9 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 42 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |